April 26, 2019 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from January 25, 2019 (vote required)
2. Approval of minutes from January 25, 2019 (vote required)
»
3. New business:Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) » - a. Anti-Allergens, oral b. Antibiotics, inhaled c. Anticoagulants d. Antidepressants, other e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs) f. Antidepressants, tricyclic g. Antihyperuricemics h. Antiparkinson agents i. Antivirals, oral/nasal j. Anxiolytics k. Beta blockers l. Bile salts m. Benign prostatic hyperplasia treatments n. Bronchodilators, beta agonist o. Chronic obstructive pulmonary disease agents p. Cough and cold agents q. Cytokine and cell-adhesion molecules antagonists r. Erythropoiesis stimulating proteins s. Glucocorticoids, inhaled t. Hereditary angioedema (HAE) treatments u. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2) v. Immune globulins, intravenous w. Lincosamides/oxazolidinones/streptogramins x. Lipotropics, other y. Lipotropics, statins z. Pulmonary arterial hypertension agents, oral and inhaled
aa. Pancreatic enzymes
bb. Pediatric vitamin preparations
cc. Prenatal vitamins
dd. Sedative hypnotics
ee. Sickle cell anemia treatments
ff. Thrombopoiesis stimulating proteins
gg. Urea Cycle Disorder, oral
3. New business:Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL) »
a. Anti-Allergens, oral b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, selective serotonin reuptake inhibitors (SSRIs)
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antiparkinson agents
i. Antivirals, oral/nasal
j. Anxiolytics
k. Beta blockers
l. Bile salts
m. Benign prostatic hyperplasia treatments
n. Bronchodilators, beta agonist
o. Chronic obstructive pulmonary disease agents
p. Cough and cold agents
q. Cytokine and cell-adhesion molecules antagonists
r. Erythropoiesis stimulating proteins
s. Glucocorticoids, inhaled
t. Hereditary angioedema (HAE) treatments
u. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2)
v. Immune globulins, intravenous
w. Lincosamides/oxazolidinones/streptogramins
x. Lipotropics, other
y. Lipotropics, statins
z. Pulmonary arterial hypertension agents, oral and inhaled
aa. Pancreatic enzymes
bb. Pediatric vitamin preparations
cc. Prenatal vitamins
dd. Sedative hypnotics
ee. Sickle cell anemia treatments
ff. Thrombopoiesis stimulating proteins
gg. Urea Cycle Disorder, oral
»
4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: » - a. Tolsura / Antifungals, oral b. Udenyca / Colony stimulating factors c. Symjepi / Epinephrine, self-injected d. Tresiba Vial / Hypoglycemics, Insulin and related agents e. ZTLido / Neuropathic pain f. Inveltys / Ophthalmic, Anti-inflammatories g. Cequa / Ophthalmic, Anti-inflammatories/Immunomodulator h. Xelpros / Ophthalmic, Glaucoma agents i. Lexette / Steroids, Topical very high j. Nuzyra Tablet / Tetracyclines
4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: »
a. Tolsura / Antifungals, oral b. Udenyca / Colony stimulating factors
c. Symjepi / Epinephrine, self-injected
d. Tresiba Vial / Hypoglycemics, Insulin and related agents
e. ZTLido / Neuropathic pain
f. Inveltys / Ophthalmic, Anti-inflammatories
g. Cequa / Ophthalmic, Anti-inflammatories/Immunomodulator
h. Xelpros / Ophthalmic, Glaucoma agents
i. Lexette / Steroids, Topical very high
j. Nuzyra Tablet / Tetracyclines
»
5. Therapeutic and clinical drug review updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
5. Therapeutic and clinical drug review updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
6. Executive work session
Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
6. Executive work session Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
»
7. Announcements of proposed drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
7. Announcements of proposed drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
8. Retrospective drug utilization review (DUR): Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Proton pump inhibitors drug use evaluation ii. Appropriate use of antibiotics b. Report on recent retrospective DUR intervention outcomes: i. Asthma disease management ii. Bipolar disease management iii. Hypertension disease management c. Retrospective DUR proposals (vote required) i. Mental health disorders management ii. Anticonvulsant drug use evaluation
8. Retrospective drug utilization review (DUR): Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Proton pump inhibitors drug use evaluation
ii. Appropriate use of antibiotics
b. Report on recent retrospective DUR intervention outcomes:
i. Asthma disease management
ii. Bipolar disease management
iii. Hypertension disease management
c. Retrospective DUR proposals (vote required)
i. Mental health disorders management
ii. Anticonvulsant drug use evaluation
»
10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) » - a. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anticholinergic drugs b. Aerosolized Agents - MDIs: Anti-Inflammatory drugs (Corticosteriods) c. Aerosolized Agents - MDIs: Beta2 Agonists (long-acting) d. Aerosolized Agents - MDIs: Beta2 Agonists (short-acting) e. Antidepressants (oral) - other f. Antidepressants (oral) - SSRIs g. Fentanyl (Inhalation/Oral/Transdermal) h. Platelet aggregation inhibitors i. Proton pump inhibitors
10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) »
a. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anticholinergic drugs b. Aerosolized Agents - MDIs: Anti-Inflammatory drugs (Corticosteriods)
c. Aerosolized Agents - MDIs: Beta2 Agonists (long-acting)
d. Aerosolized Agents - MDIs: Beta2 Agonists (short-acting)
e. Antidepressants (oral) - other
f. Antidepressants (oral) - SSRIs
g. Fentanyl (Inhalation/Oral/Transdermal)
h. Platelet aggregation inhibitors
i. Proton pump inhibitors
»
Items 9 & 11 » - 9. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) a. Arikayce (Amikacin liposome inhalation suspension) - new criteria b. HAE c. Inhaled Antibiotics - new criteria d. SGLT2 Inhibitor Agents e. Urea Cycle Disorder Agents - new criteria
Items 9 & 11 »
9. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) a. Arikayce (Amikacin liposome inhalation suspension) - new criteria
b. HAE
c. Inhaled Antibiotics - new criteria
d. SGLT2 Inhibitor Agents
e. Urea Cycle Disorder Agents - new criteria
